AMENDMENTS

In the Claims

Please amend claims 1, 10 and 22 as follows:

1. (currently amended) A method for treating an acute medical condition in a subject with a lipophilic agent, [~~comprising~~] consisting of:

providing the lipophilic agent in an oil formulation in the presence of benzyl alcohol, and

administering the formulation subcutaneously (i) to provide a peak plasma concentration of the lipophilic agent within 4 hours after the subcutaneous administration; and (ii) to achieve sustained delivery.

2. (original) The method according to claim 1, wherein the lipophilic molecule is a polycyclic phenolic compound.

3. (original) The method according to claim 2, wherein the polycyclic phenolic compound is a steroid.

Claim 4. (withdrawn)

5. (original) The method according to claim 1, wherein the lipophilic molecule is a benzo-diazapine.

6. (original) The method according to claim 5, wherein the benzodiazapine is diazepam.

7. (original) The method according to claim 1, wherein the oil is one or more vegetable oils.

~~8. (original) The method according to claim 7, wherein the vegetable oil is~~ selected from the group consisting of corn, sesame, cottonseed, soybean, poppy seed, castor, olive, canola, rapeseed, peanut, sunflower and mixtures thereof.

9. (original) A method according to claim 1, wherein the medical condition is an ischemic condition or trauma.

10. (currently amended) A method according to claim 9, wherein the ischemic condition or trauma is selected from: a stroke, [~~subarachinoid~~] subarachnoid hemorrhage, cerebrovascular injury, vasospasm, head injury, myocardial infarction and angina.

11. (original) A method according to claim 1, wherein the medical condition is an epileptic seizure.

Claims 12 – 21. (withdrawn)

22. A method of treating an acute medical condition in a subject with a non-estrogenic lipophilic agent, [~~comprising~~] consisting of:

providing the non-estrogenic lipophilic agent in an oil formulation, and administering the formulation subcutaneously (i) to provide a peak plasma concentration of the lipophilic agent within 4 hours after the subcutaneous administration; and (ii) to achieve sustained delivery.

23. A method according to claim 22, wherein the lipophilic agent is a polycyclic compound with a terminal phenol group other than estrogen.

24. A method according to claim 22, wherein the lipophilic compound is benzodiazepine.

25. A method according to claim 24, wherein the benzodiazepine is diazepam.